Oura’s offering a new wearable.
The latest: The smart ring maker now sells Dexcom’s Stelo biosensor directly through its app and website, offering continuous glucose monitors (CGMs) to 2.5M+ users.
Link up. A strategic play, this move follows Dexcom’s $75M investment into Oura and Stelo’s FDA clearance for OTC use. Now, Oura members can buy two 15-day CGMs for $99, syncing real-time glucose data with sleep, stress, activity, and meals — all in one place.
End-to-end. The CGM rollout advances Oura’s plan to become a full-stack metabolic health platform.
As part of the rollout, Oura debuted Meals and Glucose, two new features powered by Dexcom’s data and Oura’s AI advisor, delivering contextual feedback and habit coaching.
Highly refined, both Meals—a multimodal food tracker stemming from its acquisition of metabolic app Veri—and Advisor were beta-tested through Oura’s experimental wing Labs.
Platform shift. Oura’s evolution from sleep tracking to metabolic health reflects a broader trend in digital health. Hims & Hers expanded beyond hair loss and ED into GLP-1s and hormone care, while Noom shifted from weight loss to managing chronic conditions like diabetes and hypertension.
By building trust and proving outcomes, narrow solutions are becoming vertically integrated wellness operating systems, targeting high-value areas of healthcare.
Punchline: From Amazon to Life Time, selling Dexcom’s DTC CGMs signals mainstream adoption. But with seamless UX pieces in place—and backing from the hardware giant—ring/patch combos are about to be much more common.
